ACXP · CIK 0001736243 · operating
Acurx Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antibiotics for bacterial infections. The company's primary asset is ibezapolstat, a novel antibiotic candidate currently in Phase 2b clinical trials for treating Clostridioides difficile infections. The drug candidate operates through a distinct mechanism of action, targeting polymerase IIIC enzyme. The company is also developing ACX-375C, a potential oral and parenteral antibiotic targeting gram-positive bacterial pathogens including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Additionally, Acurx maintains a pipeline of candidates designated as CCP for gram-positive infections.
As a pre-revenue clinical-stage entity, Acurx does not currently generate commercial revenue from product sales. The company is incorporated in Delaware and headquartered in Staten Island, New York, with a minimal operational footprint of four full-time employees. The company was incorporated in 2017 and is listed on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.87 | $-0.87 | +24.3% | |
| 2023 | $-1.15 | $-1.15 | -2.7% | |
| 2022 | $-1.12 | $-1.12 | +24.8% | |
| 2021 | $-1.49 | $-1.49 | — |